Chandra Bhagat PharmaBOM:542934 +4.81%69 EBITDA Margin % is 5.73% as of Mar. 2026, which is 28% above its 10-year median of 4.48. GuruFocus rates BOM:542934 with a GF Score™ of 69/100 and a GF Value™ of ₹70.22 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 60.68% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chandra Bhagat Pharma EBITDA Margin % Related Terms
Chandra Bhagat Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542934 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chandra Bhagat Pharma (BOM:542934) has a EBITDA Margin % of 5.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chandra Bhagat Pharma and its competitors. This is 28% above median its historical median of 4.48. Over the past decade, Chandra Bhagat Pharma's EBITDA Margin % has ranged from 1.82 to 6.20. According to the industry distribution chart, Chandra Bhagat Pharma ranks #46 out of 117 companies in the Medical Distribution industry, placing it in the top 39.3%.
Is Chandra Bhagat Pharma's EBITDA Margin % too high?
Chandra Bhagat Pharma's current EBITDA Margin % of 5.73% is 28% above median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 6.20. The Medical Distribution industry median EBITDA Margin % is 4.28. Chandra Bhagat Pharma's value of 5.73% is 33.9% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #46 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #46 out of 117 companies for EBITDA Margin %. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median EBITDA Margin % is 4.28. Chandra Bhagat Pharma's value of 5.73% is 33.9% above this benchmark. Historically, Chandra Bhagat Pharma's own EBITDA Margin % has ranged from 1.82 to 6.20 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 4.28, Chandra Bhagat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current EBITDA Margin % of 5.73% is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current EBITDA Margin % is 5.73%, which is 28% above median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.22, compared to a current price of ₹46.00 — trading 34.5% below its estimated fair value. The current EBITDA Margin % is 5.73%, which is 28% above median its 10-year median of 4.48 and 33.9% above the Medical Distribution industry median of 4.28. Chandra Bhagat Pharma's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current EBITDA Margin % is 5.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹46.00 is trading 34.5% below its estimated GF Value™ of ₹70.22.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
EBITDA Margin %: 5.73% (28% above median its 10-year median of 4.48)
GF Value™: ₹70.22 vs. price of ₹46.00 (34.5% below fair value)
Industry Position: 33.9% above the Medical Distribution median (#46 of 117)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
69GF Score
Get the complete analysis for BOM:542934
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
